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Pioderma Gangrenoso Orbitário Fatal com 




RESUMO – O pioderma gangrenoso é uma doença inflamatória crónica que se caracteriza pelo desenvolvimento de uma 
úlcera dolorosa e profunda com bordos mal delimitados. Cabeça e pescoço são regiões anatómicas raramente atingidas e 
geralmente associadas a um pior prognóstico. A corticoterapia é a base do tratamento desta dermatose, embora as opções 
disponíveis não sejam específicas nem inteiramente eficazes no pioderma gangrenoso. Relatamos o caso de um doente de 
46 anos com pioderma gangrenoso orbitário de caráter agressivo, com extensão progressiva ao sistema nervoso central e 
resposta insuficiente ao tratamento, que culminou na morte do doente.    
PALAVRAS-CHAVE – Doenças Orbitárias; Doenças do Sistema Nervoso Central; Pioderma Gangrenoso.
Fatal Orbital Pyoderma Gangrenosum with Central 
Nervous System Involvement  
ABSTRACT – Pyoderma gangrenosum is a chronic inflammatory disease characterized by the development of a painful 
deep ulcer with undermined borders. Head and neck are rarely affected regions of the body and also usually associated 
with a worse prognosis. Corticosteroids are the mainstay of treatment although available options are not specific nor 
completely effective in  pyoderma gangrenosum. We report the case of a 46-year-old patient with an aggressive orbital 
pyoderma gangrenosum with progressive extension to the central nervous system and insufficient response to treatment, 
ultimately leading to patient’s death. 
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Pyoderma gangrenosum (PG) is a rare chronic inflam-
matory dermatosis of unknown etiology (1-4). It usually 
starts as a pustule or a nodule that progressively enlarges, 
developing central necrosis and culminating in a painful 
deep ulcer with raised and undermined borders.1-3,5 There 
is frequently a purulent and hemorrhagic discharge.1 
CASE REPORT
A 46-year-old male with a history of alcoholic liver di-
sease presented with an extensive and friable ulcer of the 
right upper eyelid with exuberant periorbital edema (Fig. 
1). The lesion was present for two years with progressive 
growth. Prior to our observation, he had been submitted 
to five surgical interventions, in Ophthalmology and Plas-
tic Surgery, due to malignant suspicion, which was exclu-
ded in all histologic exams. Infectious causes were ruled 
out through immunohistochemistry assays (Warthin-Starry, 
PAS, PAS-D, Giemsa, Grocott) and bacterial, mycobacterial 
and fungal cultures of affected tissue. Screening for HIV 
and viral hepatitis as well as immunologic study, including 
antinuclear antibody titer, anti-neutrophilic cytoplasmic an-
tibodies, antiphospholipid antibody and rheumatoid fac-
tor, were negative. Computed tomography scan showed 
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an expansive orbital lesion with invasion of the eye globe 
(Fig. 2). Due to this dramatic evolution, the hypothesis of a 
pyoderma gangrenosum was placed and corroborated by 
revision of the histological specimens (Fig. 3). We initiated 
prednisolone 1 mg/kg/day with slight clinical and radiolo-
gical improvement after a few days. Treatment was main-
tained during one month, but after prompt response, the 
lesion progressed, reaching the right forehead and eye-
brows. At this time, the patient was hospitalized for clinical 
stabilization. He had a positive interferon-gamma release 
assay (IGRA), making immediate biologic treatment unfea-
sible. Therefore, we started oral cyclosporine 300 mg/day 
in combination with oral corticosteroid. Imaging control 
through magnetic resonance imaging showed progression 
to the frontal sinuses and central nervous system, causing a 
mass effect without consequences in patient´s neurological 
state. Dexamethasone 4 mg three times daily was started 
and cyclosporine was increased to 350 mg/day, with negli-
gible benefit (Fig. 4). Cyclosporine was discontinued after 
one month due to a Pneumocystis jiroveci pneumonia, trea-
ted with trimethoprim/sulfamethoxazol. Patient's consciou-
sness had a rapid deterioration due to progressive cerebral 
edema, unsuccessfully treated with mannitol. Pneumonia 
evolved with septic shock and multi-organ dysfunction. The 
infectious complication in association with the evolution of 
the lesion ultimately led to patient's death.
DISCUSSION
PG usually affects adult patients, with a female predomi-
nance and a peak incidence between 30 and 50 years.6 The 
disease may develop in association with systemic diseases as 
inflammatory bowel disease (IBD), polyarthritis, and lympho-
proliferative disorders, but can also rise in the absence of an 
underlying disease,1,3,4,6 as in the present case. 
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Figure 1 - Extensive ulcer of the right upper eyelid with periorbital 
edema.
Figure 2 - CT scan showing expansive orbital lesion with invasion of 
the globe of the eye.
Figure 3 - Histological	findings	showing	a	predominantly	neutrophilic	
infiltrate	in	the	dermis	(HE,	400x).
Figure 4 - Deep ulcer of the right upper eyelid with irregular borders 
and a necrotic center. 
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The most frequently affected anatomic regions are the 
trunk and lower extremities but PG can develop in other 
areas.1,7 There are a few previous case reports of central 
nervous system involvement in patients with PG, although 
usually representing independent foci of attainment.8,9 Ma-
lignant pyoderma is a term used to describe a rapidly evol-
ving ulcer in the head and neck without previous history of 
systemic disorders, which is considered by many authors 
to be a rare subtype of PG.5,10,11 This variant may show 
some particularities, namely the absence of undermined 
borders, worse response to treatment and more frequent 
relapses.5,11 The designation seems appropriate since it hi-
ghlights the rapidly invasive nature of PG making crucial 
both an early diagnosis and aggressive treatment. 
PG is a neutrophilic dermatosis and its pathophysiology 
is probably multifactorial.4,10 Defects in neutrophil chemo-
taxis were classically linked to PG development, although 
altered neutrophil structure and abnormal integrin-endo-
thelial interactions may also contribute to the increased 
migration of the inflammatory cells.4,10 Previous studies 
suggest that T cells are also abundant in PG lesions but 
specific antigen responsible for T-cell activation is still unk-
nown.4,10 More recent theories classify this entity as an au-
to-inflammatory disease due to dysregulation of the innate 
immune system.4,10  
Pathergy, a phenomenon where minor trauma leads to 
the development of a new lesion or aggravation of exis-
ting ones, is a feature in 20% to 30% of the patients with 
PG.1,4,12 This patient’s surgical interventions prior to a defi-
nitive diagnosis, may have been partly responsible for the 
progressive worsening of the disease.
PG is no longer a diagnosis of exclusion, according to 
a recent consensus.13 Authors consider a skin biopsy with 
neutrophilic infiltrate a major criteria for the diagnosis al-
though a mixed infiltrate or the presence of leukocytoclastic 
vasculitis do not exclude the disease.13 Eight clinical and la-
boratorial findings are considered minor criteria (exclusion 
of infection; pathergy; personal history of IBD or arthritis; 
history of a papule, pustule or vesicule with subsequent ul-
ceration; perilesional erythema, undermining borders and 
local tenderness; multiple ulcerations; cribriform or wrink-
led scars in healed skin; response to immunosupressive 
therapy).13 Our patient presented 1 major and 4 minor cri-
teria for PG according to these newly proposed criteria. 
The clinical course of PG is unpredictable, with some 
patients experiencing a rapid development of the skin le-
sions whereas others have a more protracted evolution.1 
The mortality rate may be up to 30% with male sex, older 
age, bullous PG and association with hematological malig-
nancy being considered poor prognostic factors.1,11 
Treatment is not specific nor consistently effective.1,6 
Proper wound care and pain management are crucial to 
increase patient comfort.3 Topical drugs may be useful in 
mild cases while systemic treatments should be considered 
in more aggressive and extensive lesions.1,5 A previous re-
view suggests that combination therapy seems to be more 
effective than monotherapy.6 Although there are no syste-
matic analyses on systemic drugs used in PG, corticosteroi-
ds, dapsone, cyclosporine and other immunosuppressive 
drugs are commonly used.1,5,7 Infliximab is an option for 
refractory PG.1,3 
In our patient, refractory PG along with a rarely des-
cribed central nervous system involvement contributed to 
his earlier death although infectious intercurrence had a 
predominant role in this outcome. Despite our several the-
rapeutic options, the disease revealed resistant probably 
due to a significant delay in the diagnosis. Patient’s co-
morbidities also limited our decisions throughout the cli-
nical evolution. Therefore, this case wants to emphasize 
that dermatologists should be highly alert to unusual sites 
of involvement and atypical clinical presentations of PG, 
which may otherwise lead to delays in diagnosis and ade-
quate treatment, with possible fatal outcomes. Moreover, 
surgeons should be alert to avoid repeated surgical proce-
dures in this disease.
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